• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Biological activity of 1 alpha,25-dihydroxyergocalciferol in rachitic chicks and in rats.

作者信息

Rambeck W A, Weiser H, Zucker H

出版信息

Int J Vitam Nutr Res. 1984;54(2-3):135-9.

PMID:6334061
Abstract

The bioactivity of chemically synthesized 1 alpha,25-dihydroxyergocalciferol (1,25(OH)2D2) was investigated in rachitic chicks and in vitamin D-deficient rats. In prophylactic and in curative chick assays 1,25(OH)2D2 is about 10 times less active than 1 alpha,25-dihydroxycholecalciferol (1,25(OH)2D3). Since in the same bioassay vitamin D2 is more than 80 times less active than vitamin D3, discrimination against vitamin D2 in chickens must occur at two points, before and after the formation of 1,25(OH)2D2. Receptor binding studies revealed that the chick duodenal receptor binds 1,25(OH)2D2 with the same capacity as 1,25(OH)2D3. In rats 1,25(OH)2D2 proved to have the same antirachitic activity as 1,25(OH)2D3 and might become of therapeutic interest for application in man and domestic animals if the expectations of lower toxicity are confirmed.

摘要

相似文献

1
Biological activity of 1 alpha,25-dihydroxyergocalciferol in rachitic chicks and in rats.
Int J Vitam Nutr Res. 1984;54(2-3):135-9.
2
Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.靶器官(肠道、肾脏和骨骼)对1,25 - 二羟维生素D3及其两种类似物的选择性生物学反应。
Cancer Res. 1993 Sep 1;53(17):3935-42.
3
Biological activity of 1,25-dihydroxyvitamin D2 and 24-epi-1,25-dihydroxyvitamin D2.1,25-二羟基维生素D2和24-表-1,25-二羟基维生素D2的生物活性
Am J Physiol. 1988 Apr;254(4 Pt 1):E402-6. doi: 10.1152/ajpendo.1988.254.4.E402.
4
Healing of rachitic lesions in chicks by 24R,25-dihydroxycholecalciferol administered locally into bone.通过将24R,25 - 二羟基胆钙化醇局部注入骨骼来治愈雏鸡的佝偻病病变。
J Bone Miner Res. 1987 Apr;2(2):91-8. doi: 10.1002/jbmr.5650020203.
5
The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.新型类似物1,24(S)-二羟基维生素D2在癌细胞系生长调节方面与1,25-二羟基维生素D3具有同等效力。
Anticancer Res. 1998 May-Jun;18(3A):1769-75.
6
Displacement potency of vitamin D2 analogs in competitive protein-binding assays for 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D3, and 1,25-dihydroxyvitamin D3.维生素D2类似物在25-羟基维生素D3、24,25-二羟基维生素D3和1,25-二羟基维生素D3竞争性蛋白结合试验中的置换效力。
J Clin Endocrinol Metab. 1980 Apr;50(4):773-5. doi: 10.1210/jcem-50-4-773.
7
The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.25-羟基维生素D3和19-去甲-1α,25-二羟基维生素D2作为前列腺癌治疗药物的体外评价
Clin Cancer Res. 2000 Mar;6(3):901-8.
8
[Comparative antirachitic activity of vitamins D2 and D3 in the body of chicks].[雏鸡体内维生素D2和D3的抗佝偻病活性比较]
Prikl Biokhim Mikrobiol. 1981 Sep-Oct;17(5):712-9.
9
The vitamin D hormone and its nuclear receptor: molecular actions and disease states.维生素D激素及其核受体:分子作用与疾病状态。
J Endocrinol. 1997 Sep;154 Suppl:S57-73.
10
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.

引用本文的文献

1
Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.维生素D介导的高钙血症:机制、诊断与治疗
Endocr Rev. 2016 Oct;37(5):521-547. doi: 10.1210/er.2016-1070. Epub 2016 Sep 2.
2
Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo.1α,25 - 二羟基维生素D3和24R,25 - 二羟基维生素D3对体内生长板软骨中金属蛋白酶活性和细胞成熟的影响
Endocrine. 2001 Apr;14(3):311-23. doi: 10.1385/endo:14:3:311.